155 related articles for article (PubMed ID: 1510396)
21. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Balzarini J; Karlsson A; De Clercq E
Mol Pharmacol; 1993 Oct; 44(4):694-701. PubMed ID: 7694068
[TBL] [Abstract][Full Text] [Related]
22. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
Arion D; Fletcher RS; Borkow G; Camarasa MJ; Balzarini J; Dmitrienko GI; Parniak MA
Mol Pharmacol; 1996 Nov; 50(5):1057-64. PubMed ID: 8913335
[TBL] [Abstract][Full Text] [Related]
23. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
[TBL] [Abstract][Full Text] [Related]
24. Computational analysis of aza analogues of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranose]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) (TSAO) as HIV-1 reverse transcriptase inhibitors: relevance of conformational properties on the inhibitory activity.
Soriano E; Marco-Contelles J; Tomassi C; Nguyen Van Nhien A; Postel D
J Chem Inf Model; 2006; 46(4):1666-77. PubMed ID: 16859298
[TBL] [Abstract][Full Text] [Related]
25. Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K; Schmit JC; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez MJ; Camarasa MJ; Esnouf RM; Aquaro S; Cenci A; Perno CF; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):825-33. PubMed ID: 10875608
[TBL] [Abstract][Full Text] [Related]
26. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
27. Quantitative structure-activity relationship studies on some viral reverse transcriptase inhibitors acting as anti-HIV-1 agents.
Garg R; Gupta SP
J Enzyme Inhib; 1997 Jan; 11(3):171-81. PubMed ID: 9204386
[TBL] [Abstract][Full Text] [Related]
28. Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants.
Balzarini J; Karlsson A; Sardana VV; Emini EA; Camarasa MJ; De Clercq E
Proc Natl Acad Sci U S A; 1994 Jul; 91(14):6599-603. PubMed ID: 7517553
[TBL] [Abstract][Full Text] [Related]
29. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.
Balzarini J; Karlsson A; Meichsner C; Paessens A; Riess G; De Clercq E; Kleim JP
J Virol; 1994 Dec; 68(12):7986-92. PubMed ID: 7525984
[TBL] [Abstract][Full Text] [Related]
30. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 2',3'-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
Lin TS; Luo MZ; Liu MC; Pai SB; Dutschman GE; Cheng YC
J Med Chem; 1994 Mar; 37(6):798-803. PubMed ID: 8145230
[TBL] [Abstract][Full Text] [Related]
32. Unusual lability of 5'-O-tert-butyldimethylsilyl group on 4''-acyl TSAO derivatives.
de Castro S; Pérez-Pérez MJ; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):959-61. PubMed ID: 14565321
[No Abstract] [Full Text] [Related]
33. Asymmetric synthesis and biological evaluation of beta-L-(2R,5S)- and alpha-L-(2R,5R)-1,3-oxathiolane-pyrimidine and -purine nucleosides as potential anti-HIV agents.
Jeong LS; Schinazi RF; Beach JW; Kim HO; Nampalli S; Shanmuganathan K; Alves AJ; McMillan A; Chu CK; Mathis R
J Med Chem; 1993 Jan; 36(2):181-95. PubMed ID: 8423591
[TBL] [Abstract][Full Text] [Related]
34. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
Herdewijn P; Balzarini J; Baba M; Pauwels R; Van Aerschot A; Janssen G; De Clercq E
J Med Chem; 1988 Oct; 31(10):2040-8. PubMed ID: 3172142
[TBL] [Abstract][Full Text] [Related]
36. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.
Balzarini J; Karlsson A; Pérez-Pérez MJ; Camarasa MJ; De Clercq E
Virology; 1993 Oct; 196(2):576-85. PubMed ID: 7690501
[TBL] [Abstract][Full Text] [Related]
37. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and antiviral evaluation of 4'-C-azidomethyl-beta-D-ribofuranosyl purine and pyrimidine nucleosides.
Griffon JF; Dumas A; Storer R; Sommadossi JP; Gosselin G
Nucleosides Nucleotides Nucleic Acids; 2009 May; 28(5):435-49. PubMed ID: 20183594
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of [(2'S, 3'S)-bis(hydroxylmethyl)pyrrolidin-1-yl] purine and pyrimidine nucleosides as potential antiviral agents.
Oohashi T; Nishiyama S; Yamamura S; Kato K
Bioorg Med Chem Lett; 1998 May; 8(10):1187-8. PubMed ID: 9871732
[TBL] [Abstract][Full Text] [Related]
40. In search of a selective antiviral chemotherapy.
De Clercq E
Clin Microbiol Rev; 1997 Oct; 10(4):674-93. PubMed ID: 9336668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
